Magnesium deficiency and proton-pump inhibitor use: A clinical review

Journal of Clinical Pharmacology

Volumn 56, Issue 6, 2016, Pages 660-668

  William, Jeffrey H ^a   Danziger, John ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

hypomagnesemia; magnesium; proton pump inhibitor

Indexed keywords

MAGNESIUM; PROTON PUMP INHIBITOR;

CLINICAL DECISION MAKING; DISEASE ASSOCIATION; HEART ARRHYTHMIA; HUMAN; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAGNESIUM DEFICIENCY; MAGNESIUM DEPLETION; MAGNESIUM EXCRETION; MAGNESIUM INTAKE; MALABSORPTION; PEAFOWL; PREVALENCE; REVIEW; RISK FACTOR; SEIZURE; ANIMAL; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; INTESTINE ABSORPTION; METABOLISM; OBSERVATIONAL STUDY; PHYSIOLOGY; PROCEDURES;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INTESTINAL ABSORPTION; MAGNESIUM DEFICIENCY; OBSERVATIONAL STUDIES AS TOPIC; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84952837781     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.672     Document Type: Review

References (57)

1. de Baaij JH, Hoenderop JG, Bindels RJ,. Magnesium in man: implications for health and disease. Physiol Rev. 2015; 95: 1-46.
2. Hardwick LL, Jones MR, Buddington RK, Clemens RA, Lee DB,. Comparison of calcium and magnesium absorption: in vivo and in vitro studies. Am J Physiol. 1990; 259 (5 Pt 1): G720-726.
3. Schweigel M, Martens H,. Magnesium transport in the gastrointestinal tract. Front Biosci. 2000; 5: D666-677.
4. 2+ homeostasis by TRPM7. Cell. 2003; 114 (2): 191-200.
5. Nadler MJ, Hermosura MC, Inabe K, et al., LTRPC7 is a Mg·ATP-regulated divalent cation channel required for cell viability. Nature. 2001; 411 (6837): 590-595.
6. Graham LA, Caesar JJ, Burgen AS,. Gastrointestinal absorption and excretion of Mg 28 in man. Metabolism. 1960; 9: 646-659.
7. Quamme GA., Magnesium homeostasis and renal magnesium handling. Miner Electrolyte Metab. 1993; 19 (4-5): 218-225.
8. Quamme GA., Renal magnesium handling: new insights in understanding old problems. Kidney Int. 1997; 52 (5): 1180-1195.
9. Konrad M, Schaller A, Seelow D, et al., Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet. 2006; 79 (5): 949-957.
10. Hou J, Renigunta A, Gomes AS, et al., Claudin-16 and claudin-19 interaction is required for their assembly into tight junctions and for renal reabsorption of magnesium. Proc Natl Acad Sci USA. 2009; 106 (36): 15350-15355.
11. 2+ absorption. J Biol Chem. 2004; 279 (1): 19-25.
12. Thebault S, Cao G, Venselaar H, Xi Q, Bindels RJ, Hoenderop JG,. Role of the alpha-kinase domain in transient receptor potential melastatin 6 channel and regulation by intracellular ATP. J Biol Chem. 2008; 283 (29): 19999-20007.
13. Tong GM, Rude RK,. Magnesium deficiency in critical illness. J Intens Care Med. 2005; 20 (1): 3-17.
14. Graber ML., Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis. 1995; 25 (6): 973.
15. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW,. Omeprazole and refractory hypomagnesaemia. BMJ. 2008; 337: a425.
16. Kuipers MT, Thang HD, Arntzenius AB,. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med. 2009; 67 (5): 169-172.
17. Cundy T, Dissanayake A,. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69: 338-341.
18. Levine BS, Coburn JW,. Magnesium, the mimic/antagonist to calcium. N Engl J Med. 1984; 310 (19): 1253-1255.
19. Rude RK, Oldham SB, Singer FR,. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol (Oxf). 1976; 5 (3): 209-224.
20. Schlingmann KP, Weber S, Peters M, et al., Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet. 2002; 31 (2): 166-170.
21. Schlingmann KP, Sassen MC, Weber S, et al., Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J Am Soc Nephrol. 2005; 16 (10): 3061-3069.
22. Joffres MR, Reed DM, Yano K,. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu Heart Study. Am J Clin Nutr. 1987; 45 (2): 469-475.
23. Moskowitz A, Lee J, Donnino MW, Mark R, Celi LA, Danziger J,. The association between admission magnesium concentrations and lactic acidosis in critical illness. J Intens Care Med. 2014; Epub ahead of print.
24. Hatzistavri LS, Sarafidis PA, Georgianos PI, et al., Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens. 2009; 22 (10): 1070-1075.
25. Patki PS, Singh J, Gokhale SV, Bulakh PM, Shrotri DS, Patwardhan B,. Efficacy of potassium and magnesium in essential hypertension: a double-blind, placebo controlled, crossover study. BMJ. 1990; 301 (6751): 521-523.
26. Cappuccio FP, Markandu ND, Beynon GW, Shore AC, Sampson B, MacGregor GA,. Lack of effect of oral magnesium on high blood pressure: a double blind study. BMJ. 1985; 291 (6490): 235-238.
27. Peacock JM, Folsom AR, Arnett DK, Eckfeldt JH, Szklo M,. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 1999; 9 (3): 159-165.
28. Khan AM, Sullivan L, McCabe E, Levy D, Vasan RS, Wang TJ,. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J. 2010; 160 (4): 715-720.
29. Reffelmann T, Dorr M, Ittermann T, et al., Low serum magnesium concentrations predict increase in left ventricular mass over 5 years independently of common cardiovascular risk factors. Atherosclerosis. 2010; 213 (2): 563-569.
30. Reffelmann T, Ittermann T, Dorr M, et al., Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011; 219 (1): 280-284.
31. Chiuve SE, Sun Q, Curhan GC, et al., Dietary and plasma magnesium and risk of coronary heart disease among women. J Am Heart Assoc. 2013; 2 (2): e000114.
32. Epstein M, McGrath S, Law F,. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355 (17): 1834-1836.
33. FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm. Accessed August 3, 2015.
34. Luk CP, Parsons R, Lee YP, Hughes JD,. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother. 2013; 47: 773-780.
35. Danziger J, William JH, Scott DJ, et al., Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013; 83: 692-699.
36. Gau JT, Yang YX, Chen R, Kao TC,. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf. 2012; 21 (5): 553-559.
37. Zipursky J, Macdonald EM, Hollands S, et al., Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med. 2014; 11: e1001736.
38. Lindner G, Funk GC, Leichtle AB, et al., Impact of proton pump inhibitor use on magnesium homoeostasis: a cross-sectional study in a tertiary emergency department. Int J Clin Pract. 2014; 68 (11): 1352-1357.
39. Markovits N, Loebstein R, Halkin H, et al., The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol. 2014; 54 (8): 889-895.
40. Koulouridis I, Alfayez M, Tighiouart H, et al., Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis. 2013; 62 (4): 730-737.
41. Faulhaber GA, Ascoli BM, Lubini A, et al., Serum magnesium and proton-pump inhibitors use: a cross-sectional study. Rev Assoc Med Bras. 2013; 59 (3): 276-279.
42. Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE,. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015; 60 (8): 2280-2286.
43. Chen KP, Lee J, Mark RG, et al., Proton pump inhibitor use is not associated with cardiac arrhythmia in critically ill patients. J Clin Pharmacol. 2015; 55 (7): 774-779.
44. Yang SD, Chen Q, Wei HK, et al., Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med. 2015; 8 (4): 4899-4910.
45. Abrahamsen B, Eiken P, Eastell R,. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011; 171 (11): 998-1004.
46. Kwok CS, Yeong JK, Loke YK,. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011; 48 (4): 768-776.
47. Lee J, Youn K, Choi NK, et al., A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol. 2013; 48 (9): 1016-1022.
48. William JH, Nelson R, Hayman N, Mukamal KJ, Danziger J,. Proton-pump inhibitor use is associated with lower urinary magnesium excretion. Nephrology (Carlton). 2014; 19 (12): 798-801.
49. Thongon N, Krishnamra N,. Omeprazole decreases magnesium transport across Caco-2 monolayers. World J Gastroenterol. 2011; 17 (12): 1574-1583.
50. Lameris AL, Hess MW, van Kruijsbergen I, Hoenderop JG, Bindels RJ,. Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6. Pflugers Arch. 2013; 465 (11): 1613-1620.
51. 2+ permeability and pH sensitivity in TRPM6 and TRPM7. J Biol Chem. 2007; 282 (35): 25817-25830.
52. Mackay JD, Bladon PT,. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. Q J Med. 2010; 103 (6): 387-395.
53. Van Ende C, Van Laecke S, Marechal C, et al., Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. J Nephrol. 2014; Epub ahead of print.
54. Alhosaini M, Walter JS, Singh S, Dieter RS, Hsieh A, Leehey DJ,. Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. Am J Nephrol. 2014; 39: 204-209.
55. El-Charabaty E, Saifan C, Abdallah M, et al., Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013; 6: 515-518.
56. Biyik M, Solak Y, Ucar R, et al., Hypomagnesemia among outpatient long-term proton pump inhibitor users. Am J Ther. 2014; Epub ahead of print.
57. Kim S, Lee H, Park CH, et al., Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia. Am J Ther. 2015; 22 (1): 14-21.